Sensorion SASEURONEXT: ALSEN

Sensorion Announces Confidential Submission of Draft Registration Statement to the SEC for Potential U.S. Initial Public Offering

· Issued by Sensorion SAS via Business Wire

Summary by 6ix AI

Sensorion, a clinical-stage biotechnology company developing therapies to restore hearing and treat and prevent hearing loss, confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (SEC) on or before September 16, 2026.

Key details

  • The submission is a preliminary step in Sensorion's evaluation of a potential U.S. initial public offering of its ordinary shares, including in the form of American Depositary Shares (ADSs, certificates that let U.S. investors hold shares of a foreign company).
  • Sensorion is evaluating listing the ADSs on a U.S. national exchange.
  • Form F-1 is the registration form foreign companies file with the SEC to offer shares in the U.S.

What’s still pending

  • Any offering and listing is only potential and is subject to market and other conditions.

6ix AI wrote this summary from the release below and checked it against the release.

MONTPELLIER, France & CAMBRIDGE, Mass., September 16, 2026--(BUSINESS WIRE)--Regulatory News:

Sensorion (FR001401A9Z0 – ALSEN) ("the Company") a pioneering clinical-stage biotechnology company focused on developing novel therapies to restore hearing and treat and prevent hearing loss disorders, announced today that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (the "SEC").

The confidential submission is a preliminary step in the Company's evaluation of a potential U.S. initial public offering of its ordinary shares, including in the form of American Depositary Shares ("ADSs"), and the listing of such ADSs on a U.S. national exchange, subject to market and other conditions.

This press release does not, and is not intended to, constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933.

About Sensorion
Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.

Label: SENSORION
ISIN: FR001401A9Z0
Mnemonic: ALSEN

View source version on businesswire.com: https://www.businesswire.com/news/home/20260915034926/en/

Contacts

Investor Relations
Sensorion
Nicolas Bogler, Investor Relations and Communication
[email protected]

Press Relations
Maarc Communication
Bruno Arabian / 00 33(0)6 87 88 47 26
[email protected]

View original source (Business Wire)Sensorion SAS on 6ix

Earlier from Sensorion SAS

Later from Sensorion SAS

All Sensorion SAS news releases